Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.

Cancer letters - 28 Feb 2025

Yamamoto Gaku, Tanaka Kosuke, Kamata Ryo, Saito Hitoshi, Yamamori-Morita Tomoko, Nakao Takehiro, Liu Jie, Mori Shunta, Yagishita Shigehiro, Hamada Akinobu, Shinno Yuki, Yoshida Tatsuya, Horinouchi Hidehito, Ohe Yuichiro, Watanabe Shun-Ichi, Yatabe Yasushi, Kitai Hidenori, Konno Satoshi, Kobayashi Susumu S, Ohashi Akihiro

Abstract excerpt

KRASG12C inhibitors sotorasib and adagrasib have been approved for the treatment of KRASG12C-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple resistance mechanisms. To overcome these therapeutic limitations, combination strategies that potentiate the antitumor efficacy of KRASG12C inhibitors must be developed. Through unbiased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Myeloid Cell Leukemia Sequence 1 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrimidinones

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 39725152
DOI: 10.1016/j.canlet.2024.217414

Genes

WEE1
KEAP1
STK11
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.PMID 39725152Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancerSemantic proximity Read ↗

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read ↗

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read ↗

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Semantic proximity Read ↗

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.